Grant: Research Tools and Instruments - Category 1 (<$150,000)
University of British Columbia
$36,857.00
Microwave reactor
EF 2008-09
Résumé
One of the PI's research activities has concerned, for almost three decades now, the development of new transition-metal based radiopharmaceuticals. Our group, in collaboration with Dr. M. J. Adam at TRIUMF, is focused on the generator-produced isotopes Tc-99m, and most recently Ga-68, because the corresponding generator system has been optimized and will potentially be commercialized within the next few years. (Ga radiopharmaceutical research is the subject of a Adam/Orvig NSERC CR&D application in collaboration with MDS Nordion.) This has stimulated an interest in the development of novel derivatizable chelators for gallium(III) to circumvent older, well-explored ligand systems such as NOTA and DOTA. One of the main targets of this rapidly evolving, strongly competitive field of transition metal radionuclide-based imaging agents is to optimize and shorten procedures, because of the short half-lives involved; therefore, this field has become highly interested, and also already quite successful, in the use of microwave-supported sequential synthesis. Our current radiopharmaceutical chemistry facilities at TRIUMF include one (ancient and poorly controlled) oil bath for heating as the only tool to accelerate these reactions. Clearly, there is an overwhelming need for a microwave reactor capable of sequential, multiple syntheses. Without this, we will cease to be one of the leading research groups in our field, and might also lose the financial support of the company currently supporting our research. Furthermore, the presence of microwave reactors at research facilities of our immediate competitors makes the need of such an apparatus not just imperative but also urgent.
Programme
Research Tools and Instruments - Category 1 (<$150,000)
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
375706-2009
Name nom
Orvig, Chris
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2009
Award amount
36857
Program id
EQPEQ
Program nane en
Research Tools and Instruments - Category 1 (<$150,000)
Program name fr
Outils et instruments de recherche - catégorie 1 (<150 000$)
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3603
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Bio-inorganic chemistry
Research subject fr
Chimie bio-inorganique
Partie
1
Nb partie
1
Application title
Microwave reactor
Keyword
NA
Application summary
One of the PI's research activities has concerned, for almost three decades now, the development of new transition-metal based radiopharmaceuticals. Our group, in collaboration with Dr. M. J. Adam at TRIUMF, is focused on the generator-produced isotopes Tc-99m, and most recently Ga-68, because the corresponding generator system has been optimized and will potentially be commercialized within the next few years. (Ga radiopharmaceutical research is the subject of a Adam/Orvig NSERC CR&D application in collaboration with MDS Nordion.) This has stimulated an interest in the development of novel derivatizable chelators for gallium(III) to circumvent older, well-explored ligand systems such as NOTA and DOTA. One of the main targets of this rapidly evolving, strongly competitive field of transition metal radionuclide-based imaging agents is to optimize and shorten procedures, because of the short half-lives involved; therefore, this field has become highly interested, and also already quite successful, in the use of microwave-supported sequential synthesis. Our current radiopharmaceutical chemistry facilities at TRIUMF include one (ancient and poorly controlled) oil bath for heating as the only tool to accelerate these reactions. Clearly, there is an overwhelming need for a microwave reactor capable of sequential, multiple syntheses. Without this, we will cease to be one of the leading research groups in our field, and might also lose the financial support of the company currently supporting our research. Furthermore, the presence of microwave reactors at research facilities of our immediate competitors makes the need of such an apparatus not just imperative but also urgent.